Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 247

1.

Antiretroviral treatment for children.

Eley B, Davies MA, Apolles P, Cowburn C, Buys H, Zampoli M, Finlayson H, King S, Nuttall J.

S Afr Med J. 2006 Sep;96(9 Pt 2):988-93.

2.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
3.

Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.

Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, Vlok WJ, Mntambo M, Thomas M, Nixon K, Holst HL, Karim QA, Rollins NC, Coovadia HM, Giddy J.

BMC Pediatr. 2007 Mar 17;7:13.

4.

Immunologic function and virologic suppression among children with perinatally acquired HIV Infection on highly active antiretroviral therapy.

Rutstein RM, Gebo KA, Flynn PM, Fleishman JA, Sharp VL, Siberry GK, Spector SA.

Med Care. 2005 Sep;43(9 Suppl):III15-22.

PMID:
16116305
5.

CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.

McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH.

Clin Infect Dis. 2005 Dec 1;41(11):1662-70. Epub 2005 Oct 19.

PMID:
16267741
6.
7.

Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.

Aziz N, Sokoloff A, Kornak J, Leva NV, Mendiola ML, Levison J, Feakins C, Shannon M, Cohan D.

BJOG. 2013 Nov;120(12):1534-47. doi: 10.1111/1471-0528.12226. Epub 2013 Aug 7.

8.

Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.

Resino S, Resino R, Micheloud D, Gurbindo Gutiérrez D, Léon JA, Ramos JT, Ciria L, de José I, Mellado J, Muñoz-Fernández A; Spanish Group of Paediatric HIV Infection.

Clin Infect Dis. 2006 Mar 15;42(6):862-9. Epub 2006 Feb 9.

PMID:
16477566
9.

Treatment outcome of HAART-treated patients in a resource-limited setting: the Belgrade Cohort Study.

Jevtović D, Dragovic G, Salemović D, Ranin J, Kušić J, Marinković J, Djurković-Djaković O.

Biomed Pharmacother. 2014 Apr;68(3):391-5. doi: 10.1016/j.biopha.2014.01.001. Epub 2014 Jan 15.

PMID:
24486106
10.

Initial experience of a public sector antiretroviral treatment programme for HIV-infected children and their infected parents.

Eley B, Nuttall J, Davies MA, Smith L, Cowburn C, Buys H, Hussey G.

S Afr Med J. 2004 Aug;94(8):643-6.

PMID:
15352588
11.

Viral load predicts new world health organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy, independent of CD4 T lymphocyte value.

Oliveira R, Krauss M, Essama-Bibi S, Hofer C, Robert Harris D, Tiraboschi A, de Souza R, Marques H, Succi R, Abreu T, Della Negra M, Hazra R, Mofenson LM, Siberry GK; NISDI Pediatric Study Group 2010.

Clin Infect Dis. 2010 Dec 1;51(11):1325-33. doi: 10.1086/657119. Epub 2010 Nov 1.

12.

Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.

Lohse N, Kronborg G, Gerstoft J, Larsen CS, Pedersen G, Pedersen C, Sørensen HT, Obel N.

Clin Infect Dis. 2006 Jan 1;42(1):136-44. Epub 2005 Nov 30.

PMID:
16323104
13.

Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine.

Mocroft A, Devereux H, Kinloch-de-Loes S, Wilson D, Madge S, Youle M, Tyrer M, Loveday C, Phillips AN, Johnson MA.

AIDS. 2000 Jul 28;14(11):1545-52.

PMID:
10983641
14.

Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.

Lapadula G, Cozzi-Lepri A, Marchetti G, Antinori A, Chiodera A, Nicastri E, Parruti G, Galli M, Gori A, Monforte Ad; ICONA Foundation Study.

AIDS. 2013 Mar 13;27(5):769-79. doi: 10.1097/QAD.0b013e32835cb747.

PMID:
23719349
15.
16.

The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.

Di Biagio A, Rusconi S, Marzocchetti A, Signori A, Schiavetti I, Bruzzone B, Monno L, Punzi G, Colao MG, Penco G, Zazzi M, De Luca A; ARCA Collaborative Group.

J Med Virol. 2014 Oct;86(10):1648-55. doi: 10.1002/jmv.24017. Epub 2014 Jul 11.

PMID:
25042976
17.

HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting.

Duncombe C, Kerr SJ, Ruxrungtham K, Dore GJ, Law MG, Emery S, Lange JM, Phanuphak P, Cooper DA.

AIDS. 2005 Jan 28;19(2):169-78.

PMID:
15668542
18.

Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens.

Rouet F, Fassinou P, Inwoley A, Anaky MF, Kouakoussui A, Rouzioux C, Blanche S, Msellati P; ANRS 1244/1278 Programme Enfants Yopougon.

AIDS. 2006 Nov 28;20(18):2315-9.

PMID:
17117017
19.

Clinical and immunologic outcomes of HAART-treated HIV-infected women in resource constrain settings: the Belgrade Study.

Dragović G, Salemović D, Ranin J, Nikolić J, Kušić J, Jevtović D.

Women Health. 2014;54(1):35-47. doi: 10.1080/03630242.2013.850465.

PMID:
24555810
20.

Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.

Gutierrez F, Padilla S, Masiá M, Iribarren JA, Moreno S, Viciana P, Muñoz L, Gómez Sirvent JL, Vidal F, López-Aldeguer J, Blanco JR, Leal M, Rodríguez-Arenas MA, Perez Hoyos S; CoRIS-MD.

PLoS One. 2006 Dec 20;1:e89.

Supplemental Content

Support Center